Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$38.11

-0.34 (-0.88%)

, INVA

Innoviva

$10.91

-0.15 (-1.36%)

07:06
11/21/16
11/21
07:06
11/21/16
07:06

GlaxoSmithKline files regulatory submission for FF/UMEC/VI

GlaxoSmithKline (GSK) and Innoviva (INVA) announced the filing by GSK of a regulatory submission with the US FDA for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol for patients with chronic obstructive pulmonary disease. This follows the announcement earlier this year of plans to bring forward the timing of the U.S. filing from the first half of 2018. The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long- acting beta2-adrenergic agonist, delivered once-daily in GSK's Ellipta dry powder inhaler. The US regulatory submission of the closed triple therapy comprises a New Drug Application for the maintenance treatment of patients with COPD, including chronic bronchitis and emphysema. It is based on data from the closed triple combination therapy development programme, as well as data from studies with FF, UMEC and VI either alone or in combination. A regulatory filing in the EU is planned in the coming weeks and is expected to be followed by submissions in other countries beginning in 2017. The closed triple combination of FF/UMEC/VI is not approved for use anywhere in the world.

GSK

GlaxoSmithKline

$38.11

-0.34 (-0.88%)

INVA

Innoviva

$10.91

-0.15 (-1.36%)

  • 29

    Nov

GSK GlaxoSmithKline
$38.11

-0.34 (-0.88%)

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
INVA Innoviva
$10.91

-0.15 (-1.36%)

10/31/16
COWN
10/31/16
UPGRADE
Target $15
COWN
Outperform
Innoviva upgraded to Outperform from Market Perform at Cowen
Cowen analyst Tyler Van Buren upgraded Innoviva to Outperform and raised its price target to $15 from $13 citing valuation discount and said the commercial prospects for Breo and Anoro remain stronger than ever heading into next year.

TODAY'S FREE FLY STORIES

13:15
09/22/17
09/22
13:15
09/22/17
13:15
General news
Oil Action: The weekly Baker-Hughes oil rig count »

Oil Action: The weekly…

13:15
09/22/17
09/22
13:15
09/22/17
13:15
General news
Breaking General news story  »

Dallas Federal Reserve…

TSLA

Tesla

$366.48

-7.43 (-1.99%)

13:10
09/22/17
09/22
13:10
09/22/17
13:10
Options
Heavy trading in Tesla expiring options as the skid continues »

Heavy trading in Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

13:10
09/22/17
09/22
13:10
09/22/17
13:10
General news
Treasury Options Action: bullish call buying in block trade »

Treasury Options Action:…

13:07
09/22/17
09/22
13:07
09/22/17
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 9/22 Baker-Hughes…

RHHBY

Roche

$32.04

0.09 (0.28%)

13:07
09/22/17
09/22
13:07
09/22/17
13:07
Hot Stocks
Roche reports EU approval of Tecentriq in types of lung, bladder cancer »

Roche announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

JUNO

Juno Therapeutics

$41.62

-3.59 (-7.94%)

13:05
09/22/17
09/22
13:05
09/22/17
13:05
Options
Juno Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 22

    Sep

BHGE

Baker Hughes

$36.40

-0.18 (-0.49%)

13:04
09/22/17
09/22
13:04
09/22/17
13:04
Hot Stocks
Baker Hughes reports U.S. rig count down 1 to 935 rigs »

Baker Hughes reports the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 20

    Oct

NVLN

Novelion Therapeutics

13:03
09/22/17
09/22
13:03
09/22/17
13:03
Hot Stocks
Novelion unit Aegerion settles SEC fraud charges for $4.1M »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

, JWN

Nordstrom

$46.62

0.34 (0.73%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Periodicals
Dillard's mentioned in 'vague rumors' about attempting to go-private, Kass says »

Douglas Kass of TheStreet…

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

JWN

Nordstrom

$46.62

0.34 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MMM

3M

$211.18

0.74 (0.35%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Hot Stocks
3M files patent, trademark infringement lawsuit against Thunder Finish »

3M and 3M Innovative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOSL

Fossil

$8.79

-0.21 (-2.33%)

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Options
Fossil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

CMCSA

Comcast

$37.47

0.01 (0.03%)

, FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

12:53
09/22/17
09/22
12:53
09/22/17
12:53
Hot Stocks
Box Office Battle: 'Kingsman' sequel, 'LEGO: Ninjago' look to dethrone 'It' »

After two straight…

CMCSA

Comcast

$37.47

0.01 (0.03%)

FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

VIAB

Viacom

$27.40

-0.32 (-1.15%)

SNE

Sony

$37.43

-0.035 (-0.09%)

DIS

Disney

$98.83

-0.06 (-0.06%)

CMCSK

Comcast

FOXA

21st Century Fox

$26.76

-0.11 (-0.41%)

VIA

Viacom

$38.20

-0.05 (-0.13%)

LGF.B

Lionsgate

$30.36

0.215 (0.71%)

TWX

Time Warner

$102.71

0.22 (0.21%)

LGF.A

Lionsgate

$31.57

0.32 (1.02%)

CBS

CBS

$58.85

0.06 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 22

    Oct

  • 26

    Oct

  • 02

    Nov

AAPL

Apple

$153.39

-2.68 (-1.72%)

, FSLR

First Solar

$48.76

-0.09 (-0.18%)

12:51
09/22/17
09/22
12:51
09/22/17
12:51
General news
On The Fly: Top stock stories at midday »

Stocks on Wall Street…

AAPL

Apple

$153.39

-2.68 (-1.72%)

FSLR

First Solar

$48.76

-0.09 (-0.18%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

W

Wayfair

$75.24

-6.51 (-7.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DDC

Dominion Diamond

$14.19

0.005 (0.04%)

12:49
09/22/17
09/22
12:49
09/22/17
12:49
Hot Stocks
Dominion Diamond receives court approval for plan with The Washington Companies »

Dominion Diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

, VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

12:45
09/22/17
09/22
12:45
09/22/17
12:45
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week inflows…

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

XLF

Financial Select Sector

$25.43

-0.035 (-0.14%)

XLV

Health Care Select Sector SPDR

$81.25

-0.33 (-0.40%)

IWM

iShares Trust Russell 2000 Index Fund

$144.18

0.49 (0.34%)

GLD

SPDR Gold Trust

$123.09

0.41 (0.33%)

VWO

Vanguard FTSE Emerging Markets ETF

$44.17

-0.285 (-0.64%)

TLT

iShares 20+ Year Treasury Bond Fund

$125.84

-0.07 (-0.06%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.33

-0.01 (-0.01%)

IVV

iShares Core S&P 500

$252.18

-0.184 (-0.07%)

VO

Vanguard Mid-Cap Index Fund

$145.73

0.12 (0.08%)

VB

Vanguard Small-Cap Index Fund

$138.57

0.3 (0.22%)

VBK

Vanguard Small-Cap Growth Index Fund

$150.14

0.12 (0.08%)

MDY

SPDR S&P MidCap 400 ETF

$321.08

0.75 (0.23%)

SCHA

Schwab U.S. Small-Cap ETF

$65.69

0.19 (0.29%)

SVXY

ProShares Short VIX Short-Term Futures

$89.22

-0.5004 (-0.56%)

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$93.37

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
09/22/17
09/22
12:45
09/22/17
12:45
General news
Breaking General news story  »

Week of 9/22 Baker-Hughes…

ROK

Rockwell Automation

$177.39

0.06 (0.03%)

12:40
09/22/17
09/22
12:40
09/22/17
12:40
Options
Defensive option play opened in Rockwell »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.35

0.01 (0.01%)

12:30
09/22/17
09/22
12:30
09/22/17
12:30
Options
One week put buyer in the iShares High Yield Bond ETF »

One week put buyer in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$64.11

-0.89 (-1.37%)

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Options
Activision Blizzard call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Conference/Events
FDIC to hold a teleconference »

The FDIC examination…

$NSD

NASDAQ Market Internals

12:17
09/22/17
09/22
12:17
09/22/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
09/22/17
09/22
12:16
09/22/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$144.20

0.51 (0.35%)

12:10
09/22/17
09/22
12:10
09/22/17
12:10
Options
300K puts trade in iShares Small Cap Fund driven by spread trades »

300K puts trade in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.